Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Nickolas Zaller to Opioid-Related Disorders

This is a "connection" page, showing publications Nickolas Zaller has written about Opioid-Related Disorders.

 
Connection Strength
  
 
 
5.361
  
  1. Marshall SA, Siebenmorgen LE, Youngen K, Borders T, Zaller N. Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic. J Prim Care Community Health. 2024 Jan-Dec; 15:21501319241246359.
    View in: PubMed
    Score: 0.700
  2. Pro G, Hayes C, Brown CC, Goree J, Zaller N. Individual and Health Policy Factors Associated With Positive Heroin and Opioid Treatment Response: United States, 2018. Am J Public Health. 2022 02; 112(S1):S66-S76.
    View in: PubMed
    Score: 0.613
  3. Pro G, Montgomery BEE, Zaller N. Tailoring services in opioid treatment programs for patients involved in America's criminal justice system: national associations and variation by state and Medicaid expansion status. Subst Abuse Treat Prev Policy. 2021 06 19; 16(1):50.
    View in: PubMed
    Score: 0.587
  4. Zaller N, Donadeo K, Coffey J, Zielinski M, Brinkley-Rubinstein L. Screening for Opioid Use Disorder in the Largest Jail in Arkansas: A Brief Report. J Correct Health Care. 2019 07; 25(3):214-218.
    View in: PubMed
    Score: 0.510
  5. Brinkley-Rubinstein L, Cloud D, Drucker E, Zaller N. Opioid Use Among Those Who Have Criminal Justice Experience: Harm Reduction Strategies to Lessen HIV Risk. Curr HIV/AIDS Rep. 2018 06; 15(3):255-258.
    View in: PubMed
    Score: 0.475
  6. Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, Noska A, Reddy M, Zaller N. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015 Jul 25; 386(9991):350-9.
    View in: PubMed
    Score: 0.386
  7. Zaller ND, Yokell MA, Green TC, Gaggin J, Case P. The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island. Subst Use Misuse. 2013 Jun; 48(8):590-9.
    View in: PubMed
    Score: 0.337
  8. Zaller N, McKenzie M, Friedmann PD, Green TC, McGowan S, Rich JD. Initiation of buprenorphine during incarceration and retention in treatment upon release. J Subst Abuse Treat. 2013 Aug; 45(2):222-6.
    View in: PubMed
    Score: 0.332
  9. Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011 Sep; 5(3):175-80.
    View in: PubMed
    Score: 0.298
  10. Zaller ND, Fu JJ, Bazazi AR, Rich JD. The impact of financial discharge from methadone maintenance therapy on incarceration. J Opioid Manag. 2010 Sep-Oct; 6(5):365-70.
    View in: PubMed
    Score: 0.278
  11. McKay M, Gorvine MM, Zaller N, Singh V, Goree J. Federal and Statewide Coverage for Opioid-Sparing Chronic Pain Treatments. Pain Physician. 2022 12; 25(9):E1457-E1466.
    View in: PubMed
    Score: 0.162
  12. Zaller N, Brinkley-Rubinstein L. MOUD Provision in Correctional Settings During Time of COVID-19: Prevention and Solutions. J Addict Med. 2020 12; 14(6):e290-e292.
    View in: PubMed
    Score: 0.141
  13. Brinkley-Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, Seal D. Criminal justice continuum for opioid users at risk of overdose. Addict Behav. 2018 11; 86:104-110.
    View in: PubMed
    Score: 0.117
  14. Brinkley-Rubinstein L, McKenzie M, Macmadu A, Larney S, Zaller N, Dauria E, Rich J. A randomized, open label trial of methadone continuation versus forced withdrawal in a combined US prison and jail: Findings at 12 months post-release. Drug Alcohol Depend. 2018 03 01; 184:57-63.
    View in: PubMed
    Score: 0.116
  15. Fu JJ, Zaller ND, Yokell MA, Bazazi AR, Rich JD. Forced withdrawal from methadone maintenance therapy in criminal justice settings: a critical treatment barrier in the United States. J Subst Abuse Treat. 2013 May-Jun; 44(5):502-5.
    View in: PubMed
    Score: 0.082
  16. McKenzie M, Zaller N, Dickman SL, Green TC, Parihk A, Friedmann PD, Rich JD. A randomized trial of methadone initiation prior to release from incarceration. Subst Abus. 2012; 33(1):19-29.
    View in: PubMed
    Score: 0.076
  17. Bazazi AR, Zaller ND, Fu JJ, Rich JD. Preventing opiate overdose deaths: examining objections to take-home naloxone. J Health Care Poor Underserved. 2010 Nov; 21(4):1108-13.
    View in: PubMed
    Score: 0.070
  18. Green TC, Zaller N, Palacios WR, Bowman SE, Ray M, Heimer R, Case P. Law enforcement attitudes toward overdose prevention and response. Drug Alcohol Depend. 2013 Dec 01; 133(2):677-84.
    View in: PubMed
    Score: 0.021
  19. Green TC, Bowman SE, Ray M, Zaller N, Heimer R, Case P. Collaboration or coercion? Partnering to divert prescription opioid medications. J Urban Health. 2013 Aug; 90(4):758-67.
    View in: PubMed
    Score: 0.021
  20. Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P, Friedmann PD. How does use of a prescription monitoring program change pharmacy practice? J Am Pharm Assoc (2003). 2013 May-Jun; 53(3):273-81.
    View in: PubMed
    Score: 0.021
  21. Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011 Mar; 4(1):28-41.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.